These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28592208)

  • 21. Method to estimate the approximate samples size that yield a certain number of significant GWAS signals in polygenic traits.
    Bacanu SA; Kendler KS
    Genet Epidemiol; 2018 Jul; 42(5):488-496. PubMed ID: 29761553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How genome-wide association studies (GWAS) made traditional candidate gene studies obsolete.
    Duncan LE; Ostacher M; Ballon J
    Neuropsychopharmacology; 2019 Aug; 44(9):1518-1523. PubMed ID: 30982060
    [No Abstract]   [Full Text] [Related]  

  • 23. Multigenic traits and risk assessment in pharmacology: a population approach.
    Kalow W; Ozdemir V; Tothfalusi L
    Pharmacogenomics J; 2001; 1(4):234-6. PubMed ID: 11908764
    [No Abstract]   [Full Text] [Related]  

  • 24. Genomewide Association Studies in Pharmacogenomics.
    McInnes G; Yee SW; Pershad Y; Altman RB
    Clin Pharmacol Ther; 2021 Sep; 110(3):637-648. PubMed ID: 34185318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conference Scene: The great debate: genome-wide association studies in pharmacogenetics research, good or bad?
    Bailey KR; Cheng C
    Pharmacogenomics; 2010 Mar; 11(3):305-8. PubMed ID: 20235786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Common and rare variants, polygenic traits and missing heritability].
    Jordan B
    Med Sci (Paris); 2017; 33(6-7):674-676. PubMed ID: 28990573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insight gained from genome-wide interaction and enrichment analysis on weight gain during citalopram treatment.
    Corfitsen HT; Drago A
    Neurosci Lett; 2017 Jan; 637():38-43. PubMed ID: 27899308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Progress in genetic association study for multifactorial diseases].
    Yamamoto K
    Nihon Rinsho; 2009 Jun; 67(6):1063-7. PubMed ID: 19507493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.
    Narasimhan S; Lohoff FW
    Pharmacogenomics; 2012 Mar; 13(4):441-64. PubMed ID: 22380000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomewide interaction and enrichment analysis on antidepressant response.
    Antypa N; Drago A; Serretti A
    Psychol Med; 2014 Mar; 44(4):753-65. PubMed ID: 23809733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HTR2A gene variation is involved in antidepressant treatment response.
    Lucae S; Ising M; Horstmann S; Baune BT; Arolt V; Müller-Myhsok B; Holsboer F; Domschke K
    Eur Neuropsychopharmacol; 2010 Jan; 20(1):65-8. PubMed ID: 19758789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Letter by Zheng Regarding Article, "Genome-Wide Polygenic Score and the Risk of Ischemic Stroke in a Prospective Cohort: the Hisayama Study".
    Zheng BK
    Stroke; 2020 Jul; 51(7):e128-e129. PubMed ID: 32498660
    [No Abstract]   [Full Text] [Related]  

  • 33. No association between polygenic risk for schizophrenia and brain volume in the general population.
    Van der Auwera S; Wittfeld K; Homuth G; Teumer A; Hegenscheid K; Grabe HJ
    Biol Psychiatry; 2015 Dec; 78(11):e41-2. PubMed ID: 25917135
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacogenomics of antidepressant drugs.
    Horstmann S; Binder EB
    Pharmacol Ther; 2009 Oct; 124(1):57-73. PubMed ID: 19563827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polygenic risk scores in imaging genetics: Usefulness and applications.
    Dima D; Breen G
    J Psychopharmacol; 2015 Aug; 29(8):867-71. PubMed ID: 25944849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach.
    Ruderfer DM; Charney AW; Readhead B; Kidd BA; Kähler AK; Kenny PJ; Keiser MJ; Moran JL; Hultman CM; Scott SA; Sullivan PF; Purcell SM; Dudley JT; Sklar P
    Lancet Psychiatry; 2016 Apr; 3(4):350-7. PubMed ID: 26915512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antidepressant pharmacogenetics.
    Singh AB; Bousman CA; Ng C; Berk M
    Curr Opin Psychiatry; 2014 Jan; 27(1):43-51. PubMed ID: 24270480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for a polygenic contribution to androgenetic alopecia.
    Heilmann S; Brockschmidt FF; Hillmer AM; Hanneken S; Eigelshoven S; Ludwig KU; Herold C; Mangold E; Becker T; Kruse R; Knapp M; Nöthen MM
    Br J Dermatol; 2013 Oct; 169(4):927-30. PubMed ID: 23701444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polygenic risk score as a key factor in cardiovascular clinical prediction models.
    Brion M; González-Juanatey JR; Carracedo Á
    Rev Esp Cardiol (Engl Ed); 2020 Aug; 73(8):608-610. PubMed ID: 32081626
    [No Abstract]   [Full Text] [Related]  

  • 40. Attention-deficit/hyperactivity disorder polygenic risk scores predict attention problems in a population-based sample of children.
    Groen-Blokhuis MM; Middeldorp CM; Kan KJ; Abdellaoui A; van Beijsterveldt CE; Ehli EA; Davies GE; Scheet PA; Xiao X; Hudziak JJ; Hottenga JJ; ; Neale BM; Boomsma DI
    J Am Acad Child Adolesc Psychiatry; 2014 Oct; 53(10):1123-9.e6. PubMed ID: 25245356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.